Stryker (SYK) Reiterated at Market Outperform by Citizens: Milestones Notched in FY26

Citizens analyst David Turkaly reiterated a Market Outperform rating and $440.00 price target on Stryker (NYSE: SYK).

The analyst commented, "while operations were humming throughout the year, the stock had lagged its typical performance and that of several peers. Last night, SYK again displayed executional consistency besting consensus on both the top and bottom lines in the quarter as MedSurg and Neurotech slightly outpaced Orthopaedics (the exact reversal of last quarter). Several milestones were notched in FY25, including the first year of sales coming in north of $25 bln and the fourth consecutive year of double-digit organic sales growth, which is truly impressive given that ever-expanding revenue base."

For an analyst ratings summary and ratings history on Stryker click here. For more ratings news on Stryker click here.

Shares of Stryker closed at $354.30 yesterday.

You May Also Be Interested In

• Wolfe Research Downgrades Stryker (SYK) to Peerperform
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating